Phillip P. Chan
Net Worth

Last updated:

What is Phillip P. Chan net worth?

The estimated net worth of Dr. Phillip P. Chan is at least $9,542,215 as of 13 Dec 2023. He owns shares worth $28,420 as insider, has earned $48,755 from insider trading and has received compensation worth at least $9,465,040 in Cytosorbents Corporation.

What is the salary of Phillip P. Chan?

Dr. Phillip P. Chan salary is $728,080 per year as Chief Executive Officer & Director in Cytosorbents Corporation.

How old is Phillip P. Chan?

Dr. Phillip P. Chan is 55 years old, born in 1970.

What stocks does Phillip P. Chan currently own?

As insider, Dr. Phillip P. Chan owns shares in one company:

Company Title Shares Price per share Total value
Cytosorbents Corporation (CTSO) Chief Executive Officer & Director 26,315 $1.08 $28,420

What does Cytosorbents Corporation do?

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CTSO logo
CTSO
Cytosorbents Corporation
$1.08

Phillip P. Chan insider trading

Cytosorbents Corporation

Dr. Phillip P. Chan has made 4 insider trades between 2012-2023, according to the Form 4 filled with the SEC. Most recently he purchased 26,315 units of CTSO stock worth $52,630 on 13 Dec 2023.

The largest trade he's ever made was exercising 190,000 units of CTSO stock on 4 Sep 2012. As of 13 Dec 2023 he still owns at least 26,315 units of CTSO stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock Warrant (Right to Buy) 26,315 $2 $52,630
Purchase
Common Stock 75,188 $1.33 $100,000
Option
Common Stock 30,500 $2.88 $87,688
Option
Stock Option (right to buy) 30,500 $2.88 $87,688
Purchase
Common Stock 5,859 $1.26 $7,382
Purchase
Common Stock 9,850 $1.26 $12,411
Purchase
Common Stock 14,291 $1.26 $18,064
Purchase
Common Stock 35,000 $1.7 $59,500
Purchase
Common Stock 2,221 $1.85 $4,109
Purchase
Common Stock 16,000 $2.17 $34,784
Purchase
Common Stock 5,462 $4.05 $22,121
Purchase
Common Stock 100 $4.04 $404
Purchase
Common Stock 9,438 $4.05 $38,224
Purchase
Common Stock 5,000 $5.25 $26,250
Option
Stock Option (right to buy) 14,100 N/A N/A
Option
Common Stock 14,100 N/A N/A
Purchase
Common Stock 16,500 N/A N/A
Option
Common Stock 75,000 N/A N/A
Option
Stock Option (right to buy) 75,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Stock Option (right to buy) 20,000 N/A N/A
Option
Non-Statutory Stock Option (right to buy) 89,337 N/A N/A
Option
Common Stock 89,337 N/A N/A
Sale
Common Stock 24,337 N/A N/A
Sale
Common Stock 2,731 N/A N/A
Option
Non-Statutory Stock Option (right to buy) 2,731 N/A N/A
Option
Common Stock 2,731 N/A N/A
Option
Non-Statutory Stock Option (right to buy) 2,900 N/A N/A
Sale
Common Stock 2,900 N/A N/A
Option
Common Stock 2,900 N/A N/A
Option
Non-Statutory Stock Option (right to buy) 5,787 N/A N/A
Option
Common Stock 5,787 $8.43 $48,755
Sale
Common Stock 5,787 $8.43 $48,755
Purchase
Common Stock 3,700 $4 $14,800
Purchase
Common Stock 6,300 $4 $25,200
Purchase
Common Stock 4,600 $5.4 $24,840
Purchase
Common Stock 5,000 $4.89 $24,450
Purchase
Warrants 1 $0.13 $0
Purchase
Common Stock, par value $0.001 per share 190,000 $0.13 $24,700

Cytosorbents key executives

Cytosorbents Corporation executives and other stock owners filed with the SEC:

  • Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. (57) Chief Medical Officer
  • Dr. Phillip P. Chan (55) Chief Executive Officer & Director
  • Mr. Vincent J. Capponi M.S., MS (67) Pres & Chief Operating Officer
  • Ms. Kathleen P. Bloch CPA, M.B.A., MBA, CPA (70) Chief Financial Officer & Sec.